UK markets closed

Genmab A/S (0MGB.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
2,613.00+31.74 (+1.23%)
At close: 08:35AM BST
Full screen
Previous close2,581.26
BidN/A x N/A
AskN/A x N/A
Day's range2,606.00 - 2,613.00
52-week range2,379.00 - 3,325.00
Avg. volume14,977
Market capN/A
Beta (5Y monthly)0.83
PE ratio (TTM)N/A
Earnings date01 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

    Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global casesIf approved, epcoritamab (TEPKINLY®) would become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of syst

  • Globe Newswire

    Completion of Share Buy-back Program

    Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program was expected to be completed no later than December 16, 2024. The following transactions were executed under the program from June 24, 2024, to June 26, 2024: Trading PlatformNo.

  • Business Wire

    EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

    COPENHAGEN, Denmark, June 26, 2024--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. With this approval, EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. to treat this patient population. This indication is approved und